Illumina (Illumina) Long-Term Capital Lease Obligation

: $687 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Illumina's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $687 Mil.

Illumina's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($726 Mil) to Sep. 2023 ($698 Mil) and declined from Sep. 2023 ($698 Mil) to Dec. 2023 ($687 Mil).

Illumina's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($774 Mil) to Dec. 2022 ($744 Mil) and declined from Dec. 2022 ($744 Mil) to Dec. 2023 ($687 Mil).

Illumina Long-Term Capital Lease Obligation Historical Data

The historical data trend for Illumina's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

695.00

671.00

774.00

744.00

687.00

Illumina Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation																744.00	747.00	726.00	698.00	687.00

Illumina (NAS:ILMN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Illumina Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Illumina's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina (Illumina) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ILMN:Mexico 1ILMN:Italy ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Executives

Aimee L Hoyt	officer: SVP, Chief People Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen	director, officer: Chief Executive Officer	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi	officer: SVP Product Development	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno	director	C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen	officer: VP, Chief Accounting Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell	officer: Sr VP & General Counsel	5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank	officer: Chief Public Affairs Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo	officer: SVP Chief Medical Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins	officer: SVP, Chief Information Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels	officer: Chief of Global Operations	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley	officer: President & CEO	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121